<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429737</url>
  </required_header>
  <id_info>
    <org_study_id>Chang Gung IRB 201601965A3</org_study_id>
    <nct_id>NCT04429737</nct_id>
  </id_info>
  <brief_title>The Effects of Freshwater Clam Extract on Blood Sugar, and Lipid Profile in Prediabetes Patients</brief_title>
  <official_title>Department of Traditional Chinese Medicine, Keelung Chang Gung Memorial Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhao Hong Biotechnology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the freshwater clam extract and its
      combination is effective on the improvement of glucose and lipid metabolism, also evaluate
      its ability to postpone prediabetes patients to become diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the effect of freshwater clam extract and its combination is
      effective on the improvement of glucose and lipid metabolism, as well as evaluate its ability
      to postpone prediabetes patients to become diabetes., 3 month and 6 month data will be
      collected and put into analysis to provide some suggestions on the Clam protein capsules and
      Clam peptide plus Chlorella capsules use in the clinical practice for prediabetes patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the change in lipid profile relative to baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the change in Total Cholesterol(mg/dL), Triglyceride(mg/dL), low density lipoprotein (mg/dL) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in lipid profile relative to baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the change in Total Cholesterol(mg/dL), Triglyceride(mg/dL), low density lipoprotein (mg/dL) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in inflammation index relative to baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the change in TNF-alpha (pg/ml) and hs-CRP(pg/ml) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in inflammation index relative to baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the change in TNF-alpha (pg/ml) and hs-CRP(pg/ml) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in HbA1C (%) relative to baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the change in HbA1C (%) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in HbA1C (%) relative to baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the change in HbA1C (%) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in fasting glucose (mg/dl) relative to baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the change in fasting glucose (mg/dl) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in fasting glucose (mg/dl) relative to baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the change in fasting glucose (mg/dl) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in liver function relative to baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the change in ALT (U/L) and AST(U/L) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in liver function relative to baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the change in ALT (U/L) and AST(U/L) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in renal function relative to baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the change in Bun(mg/dL),Uric acid(mg/dL) and Creatinine(mg/dL) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in renal function relative to baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the change in Bun(mg/dL), Uric acid(mg/dL) and Creatinine(mg/dL) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in Albumin (g/L) relative to baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the change in Albumin (g/L) relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in Albumin (g/L) relative to baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the change in Albumin (g/L) relative to baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Prediabetes</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Dietary Supplement</condition>
  <condition>Nutrition</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The prediabetes patients in this arm will receive Clam protein capsules or Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The prediabetes patients in this arm will receive placebo with similar appearance of Clam protein capsules or Clam peptide plus Chlorella capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>clam protein capsules</intervention_name>
    <description>The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Clam peptide plus Chlorella capsules</intervention_name>
    <description>The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Agree to cooperate in the trial and sign the written informed consent

          2. Age 25-70 years

          3. Glucose AC between 100-125 mg/dL

          4. HbA1c between 5.7%~6.4%

          5. Total Cholesterol≧160mg/dL or LDL-C≧100mg/dL Remark: Meet one of the (3)~(5)
             conditions is acceptable

        Exclusion Criteria:

          1. Pregnant and lactating women

          2. Poor medication compliance

          3. Abnormal liver function patients (ALT and AST value＞ 2 folds of normal value upper
             limit )

          4. Abnormal renal function patients (creatinine value＞1.5 mg/dL)

          5. Abnormal gastrointestinal function patients (eg. gastrostomy, enterostomy, and
             diarrhea)

          6. Sever comorbidity in the last 6 months. (eg. Brain stroke, myocardial infarction, and
             major trauma and surgery)

          7. Using influence blood sugar, blood pressure, and blood lipid drugs (eg sex hormones,
             corticosteroids, H2 blockers, diuretics and Statin )

          8. Diabetes patients

          9. Other sever diseases ( malignant tumor and alzheimer's disease)

         10. With inflammatory diseases, infectious disease, and severe immune deficiency ( eg.
             tuberculosis, AIDS, active pneumonia, systemic lupus erythematosus and rheumatoid
             arthritis)

         11. Other influence blood sugar endocrine disease (eg. Hyperthyroidism, Acromegaly,
             Cushing's syndrome and Pheochromocytoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TSE-HUNG HUANG, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for traditional chinese medicine, Chang Gung Memorial Hospital</name>
      <address>
        <city>Gueishan Township</city>
        <state>Taoyuan County</state>
        <zip>33378</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TSE-HUNG HUANG MD PhD</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Clam protein capsules</keyword>
  <keyword>Clam peptide</keyword>
  <keyword>Clam amino capsules</keyword>
  <keyword>clam extract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

